SHIPPEO
3.6.2024 10:01:28 CEST | Business Wire | Press release
Unipart, a supply chain solutions and performance improvement technologies business, has chosen Shippeo, a global leader in real-time multimodal transportation visibility as its supply chain visibility partner.
Leveraging Shippeo’s unparalleled real-time data and advanced transportation visibility technology, Unipart Logistics enhances its Lead Logistics Partner (LLP) capability to enable customers to better manage suppliers across road, sea, and air logistics, as well as warehousing and in-plant logistics. This empowers them to build resilience and reduce environmental impact across their global supply chain network.
Shippeo aggregates the industry’s largest global dataset, facilitating intelligent routing decisions across various modes of transportation worldwide. Through smarter carrier routing and management, ETA calculation, and in-transit management solutions, Shippeo will provide real-time insights, empowering users of the LLP to bolster supply chain resilience and sustainability, all while prioritising customer-centric operations. LLP users will also gain live insights into inventory, costs, OTIF, and scope 3 CO2 emissions throughout the supply chain, equipping logistics leaders with actionable data to drive informed business decisions. This continuous monitoring offers early alerts for supply chain issues and enables proactive mitigation or avoidance of disruptions.
Welcoming Unipart to Shippeo strengthens our UK presence and aligns with our shared vision for efficient, customer-centric, and sustainable supply chains. Their commitment to innovation and operational excellence perfectly complements Shippeo's real-time visibility platform. We're confident that our platform will empower Unipart to enhance their LLP platform, providing real-time visibility and control to manage their customer's supply chain, boost satisfaction, and achieve their sustainability goals. This partnership underscores our dedication to UK businesses and the increasing demand for real-time transportation visibility solutions," said Stuart Morrison, Shippeo Vice President, Northern Europe.
“Two trusted brands working in partnership delivering the complete end to end supply chain solution is critical to the success of any customer's supply chain. The need for real time visibility matched with the knowledge and expertise of Uniparts LLP offering deliver’s an efficient and sustainable solution. The data that the Shippeo system provides not only benefits the LLP and its customers for operational control, management and supply chain improvements but also supports and focuses all of our efforts on the need for a sustainable future,” said Lee Fox, Sector Strategy and Business Development Director for LLP at Unipart.
You can Shippeo and Unipart at Multimodal UK from June 11-13 in Birmingham. Don't miss the session with Shippeo’s Chief Product Officer, Anand Medepalli, and Unipart’s Director of Business Development and Sector Strategies, Adam Jones, at 10:30 AM GMT on June 11th. They will discuss "Shaping Logistics' Future: Shippeo & Unipart's Real-Time Visibility Story."
About Shippeo
Shippeo is a global leader in real-time multimodal transportation visibility, helping major shippers and logistics service providers operate more resilient, sustainable, and customer-centric supply chains. This is made possible with highly accurate real-time operational visibility and Transport Process Automation™ to streamline transportation processes, reduce latency and improve operational efficiency. Their Multimodal Visibility Network integrates with more than 1,000 TMS, telematics and ELD systems, enabling Shippeo’s platform to provide instant access to real-time shipment tracking across all transport modes, in a single portal, through an intuitive user experience. A proprietary and industry-leading machine learning algorithm offers unmatched ETA accuracy, allowing supply chain companies to quickly anticipate problems, proactively alert customers, efficiently manage exceptions with collaborative workflows, and GHG emissions from supply chain transport. Hundreds of customers, including global brands like Ahold Delhaize, AkzoNobel, Amazon, Avery Dennison, Bosch Siemens Hausgeräte, Carrefour, Coca-Cola HBC, Jaguar Land Rover, Heineken, Kuehne+Nagel, L’Oréal, LVMH, Renault Group, Sabic, Saint-Gobain, Siemens Energy and XPO Logistics, trust Shippeo to track more than 32 million shipments per year across 110 countries. Learn more at www.shippeo.com, LinkedIn, Facebook, X (formerly Twitter)
About Unipart
Unipart Group is a leading provider of supply chain solutions and performance improvement technologies. It has deep expertise and breadth of capabilities in seven core sectors – automotive, rail and public transport, technology, healthcare, aerospace and defence, e-commerce, consumer and retail, and industrial sectors.
Unipart’s customer promise is: ‘To understand the real and perceived needs of our customers better than anyone else and to serve them better than anyone else.’ At the heart of delivering this is ‘The Unipart Way’, which is demonstrated in the way colleagues think, work and behave. The Unipart Way empowers more than 12,000 colleagues across operations in the UK and 20 international markets with a continuous improvement mindset, delivering operational excellence and added value for customers, everyday.
In 2023 Unipart delivered £1bn turnover. In 2024 it is celebrating the 50th Anniversary of the Unipart brand, having been a division within British Leyland in 1974 and becoming a private company through a management buyout in 1987.
Unipart is committed to setting the highest standards for colleague safety and wellbeing and sustainability. In 2023 it became the first organisation ever to be recognised with a world-class safety, wellbeing and sustainability ‘treble’ by the British Safety Council, and had its ambitious near-term and net-zero targets validated by the Science Based Targets initiative (SBTi).
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240603664536/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release
Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
